Mengzhao N. Yang

State Key Laboratory Of Antiviral Drugs
Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Development of a machine learning-based mortality prediction model for patients with mental disorders and COVID-19.

Development of a machine learning-based mortality prediction model for patients with mental disorders and COVID-19.

Journal: Frontiers in cellular and infection microbiology

Published: February 22, 2026

Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study.

Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study.

Journal: BMC cancer

Published: August 19, 2025

Alterations of the oral mycobiome in patients with CCA.

Alterations of the oral mycobiome in patients with CCA.

Journal: BMC oral health

Published: August 03, 2025

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China.

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China.

Journal: BMJ open

Published: June 27, 2025

Red blood cell distribution width to albumin ratio predicts mortality in heart failure patients with pneumonia.

Red blood cell distribution width to albumin ratio predicts mortality in heart failure patients with pneumonia.

Journal: Frontiers in cardiovascular medicine

Published: May 31, 2025

The oral microbiome is associated with the diagnosis, prognosis and radiotherapy sensitivity of esophageal cancer.

The oral microbiome is associated with the diagnosis, prognosis and radiotherapy sensitivity of esophageal cancer.

Journal: Journal of translational medicine

Published: March 20, 2025

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases.

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases.

Journal: Virology journal

Published: January 17, 2025

A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes.

A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes.

Journal: Frontiers in endocrinology

Published: July 19, 2024

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study.

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study.

Journal: BMC infectious diseases

Published: July 13, 2024

A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years.

A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years.

Journal: Acta pharmaceutica Sinica. B

Published: June 29, 2024

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS-CoV-2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study.

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS-CoV-2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 23, 2024

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes.

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes.

Journal: iScience

Published: May 10, 2024

Showing 1-12 of 17

Last Updated: 09/26/2026